TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1846783
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 micrograms/min/100 ml forearm tissue)
Study: 1846783
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (0.6 micrograms/min/100 ml forearm tissue)
Study: 1846783
Drug: Acetylcholine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (16 micrograms/min/100 ml forearm tissue)
Study: 6357805
Drug: Adriamycin 70
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse.
Study: 6357805
Drug: Vincristine 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin.
Study: 6357805
Drug: Adriamycin 70
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse (group A).
Study: 6357805
Drug: Vincristine 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin (group AV).
Study: 6357805
Drug: Adriamycin 70
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses (group A).
Study: 30606237
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) granules (4.9 g twice daily) plus salmeterol/fluticasone propionate combination for 12 weeks
Study: 30606237
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo plus salmeterol/fluticasone propionate combination for 12 weeks
Study: 26300464
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with ingenol mebutate gel (0.015% and 0.05%)
Study: 26300464
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with ingenol mebutate gel (0.015% and 0.05%)
Study: 7552095
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol
Study: 16466169
Drug: Feiji Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feiji Recipe (FJR) and chemotherapy
Study: 12504039
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation radiation therapy (Arm A)
Study: 12504039
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation RT plus concomitant chemotherapy (Arm C)
Study: 10817001
Drug: Alfentanyl (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanyl (bolus dose of 50 micrograms.kg‐1 and continuous infusion of 0.50 microgram.kg‐1.min‐1)
Study: 10817001
Drug: Fentanyl (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (bolus dose of 5 micrograms.kg‐1 and continuous infusion of 0.16 microgram.kg‐1.min‐1)
Study: 8776186
Drug: Heparin-coated group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated group (Group H)
Study: 1498061
Drug: 9 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 intravenous CMF courses (cyclophosphamide, methotrexate, 5FU) - 113 patients
Study: 27555618
Drug: Retrograde rhinopharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrograde rhinopharyngeal clearance with physiological solution (0.9%) instillation
Study: 6502317
Drug: Fenfluramine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine 1.5 mg/kg daily (0.75 mg/kg twice daily) for 8 months
Study: 31175425
Drug: Social counseling
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social counseling and therapy led by a social worker, six sessions of 60 min each in 3 weeks
Study: 31175425
Drug: Social counseling
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social counseling and therapy led by a social worker
Study: 23066769
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 2000 mg daily
Study: 20509857
Drug: PIO (pioglitazone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIO (pioglitazone) 15 mg, twice a day
Study: 20509857
Drug: GLIM (glimepiride)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLIM (glimepiride) 1 mg, twice a day
Study: 11884967
Drug: biv‐WC (killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: biv‐WC (killed oral cholera vaccine)
Study: 11884967
Drug: rBS‐WC (commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBS‐WC (commercially available monovalent oral cholera vaccine)
Study: 1695491
Drug: Plasmodium vivax
Normalized name: Plasmodium vivax Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmodium vivax sporozoite vaccine at 10 micrograms
Study: 1695491
Drug: Plasmodium vivax
Normalized name: Plasmodium vivax Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmodium vivax sporozoite vaccine at 100 micrograms
Study: 1695491
Drug: Plasmodium vivax
Normalized name: Plasmodium vivax Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmodium vivax sporozoite vaccine at 1,000 micrograms
Study: 1695491
Drug: Plasmodium vivax
Normalized name: Plasmodium vivax Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmodium vivax sporozoite vaccine (all doses)
Study: 29336859
Drug: Chemotherapy counselling
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy counselling by pharmacists based on the 'Managing Patients on Chemotherapy' module
Study: 28510680
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron polysaccharide, 150 mg twice daily for 16 weeks
Study: 28510680
Drug: Placebo, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 150 mg twice daily for 16 weeks
Study: 28510680
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron polysaccharide
Study: 26152766
Drug: Glucagon doses
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon doses studied in both groups
Study: 21923567
Drug: Topical fusidic
Normalized name: fusidate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fusidic acid cream
Study: 21923567
Drug: Single-dose clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose clarithromycin
Study: 19102912
Drug: High density
Normalized name: High density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High density lipoprotein‐cholesterol (HDL) levels > 1.04 mmol/L in ACS patients
Study: 10824623
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's Wort extract (300 mg tablet standardized to 0.3% hypericin, taken three times a day for 14 days)
Study: 6148842
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy of dynamic type (ST)
Study: 6148843
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (R)
Study: 6148843
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal therapy (B)
Study: 31466618
Drug: Biomarker-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided therapy (NT-proBNP reduction to ≤1,000 pg/ml)
Study: 27478305
Drug: Tr14 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tr14 tablets
Study: 22510305
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW (once weekly)
Study: 20119581
Drug: Triple H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple H. pylori eradication therapy for 7 days
Study: 14655915
Drug: Metyrapone (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (4.5 g)
Study: 14655915
Drug: Metyrapone (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (6.0 g)
Study: 29843226
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg over 10 min)
Study: 26687959
Drug: Dulanermin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulanermin (8 mg/kg)
Study: 26687959
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 weekly)
Study: 16957427
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor arm
Study: 15004821
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulsed dye laser treatment to one eye
Study: 9033244
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg (0.25%) bupivacaine
Study: 9033244
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg (0.125%) bupivacaine
Study: 30265585
Drug: Topical E6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical E6005
Study: 29667099
Drug: Tapering NSAIDs
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering NSAIDs and DMARDs by 50% (group 2)
Study: 20346777
Drug: 0.18% sodium
Normalized name: Dextrose 4% and 0.18% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18% sodium hyaluronate ophthalmic solution (Rejena, Vismed)
Study: 10368336
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g glutamine in 330 ml glucose polymer solution
Study: 10368336
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine alone
Study: 10368336
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g glutamine in 330 ml placebo
Study: 6773161
Drug: Glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium
Study: 30776898
Drug: G-CPR (resuscitation-retraining
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CPR (resuscitation-retraining programme)
Study: 30776898
Drug: G-Stan (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Stan (standard programme)
Study: 26946616
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) herbs for tonifying Qi and kidney, and replenishing spleen
Study: 24784832
Drug: Low Glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Glycemic Index (LGI) snack (0.4 g carbohydrate/kg body mass)
Study: 24784832
Drug: High Glycemic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Glycemic Index (HGI) snack (0.4 g carbohydrate/kg body mass)
Study: 20823895
Drug: 50,000 U
Normalized name: Decara 50,000 UNT Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 U oral cholecalciferol monthly (1600 U/day)
Study: 20823895
Drug: 50,000 U
Normalized name: Decara 50,000 UNT Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 U oral cholecalciferol bimonthly (800 U/day)
Study: 15834750
Drug: Vitek 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitek 2 system (bioMerieux, Marcy l'Etoile, France)
Study: 12495243
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training twice per week (n = 20)
Study: 9523803
Drug: 1.5% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% mepivacaine (45 mg)
Study: 9523803
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (60 mg)
Study: 2692654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide and tamoxifen
Study: 202425
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium oxide
Study: 26369888
Drug: Higher tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tidal volume (20 ml kg(‐1) ideal body weight)
Study: 26369888
Drug: Standard tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tidal volume (10 ml kg(‐1) ideal body weight)
Study: 25179854
Drug: Traditional center-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional center-based exercise therapy (TRAD)
Study: 20820932
Drug: CRD-UFA (47
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRD-UFA (47 g SFA/d)
Study: 20820932
Drug: CRD-SFA (86
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRD-SFA (86 g/d SFA)
Study: 9098014
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg)
Study: 8546475
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of granisetron and methylprednisolone (MP: 10 mg/kg)
Study: 2070983
Drug: New low-sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: New low-sodium cleansing solution
Study: 2070983
Drug: Standard polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polyethylene glycol solution
Study: 2070983
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both solutions
Study: 28530840
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg subcutaneously every 4 weeks or every 8 weeks)
Study: 23432408
Drug: L. casei
Normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. casei strain Shirota fermented milk
Study: 21352464
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg
Study: 25583754
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg
Study: 17727393
Drug: Talnetant 25
Normalized name: Talnetant
DrugBank: Talnetant (DB06429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talnetant 25 mg
Study: 17727393
Drug: Talnetant 100
Normalized name: Talnetant
DrugBank: Talnetant (DB06429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talnetant 100 mg
Study: 9680900
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate (0.05%)‐sodium fluoride (0.04%)‐strontium (100 ppm as SrCl2) rinsing solution (CXFSr)
Study: 7844233
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (150 mg or 300 mg daily) starting from day 13 of HRT
Study: 7844233
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin starting from day 1 of HRT
Study: 1097194
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg chlorthalidone daily
Study: 28697102
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g secnidazole
Study: 28697102
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g secnidazole
Study: 25858178
Drug: Brief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief treatment programme (3 sessions of breathing retraining and education)
Study: 23686891
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect-site concentration of 1.5 ng/mL (R1.5)
Study: 23686891
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect-site concentration of 2 ng/mL (R2)
Study: 23686891
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect-site concentration of 1 ng/mL (R1)
Study: 21401801
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (3‐monthly spirometry with medical review)
Study: 19824278
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TF)
Study: 18060626
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + atorvastatin (10 mg/day)
Study: 15544079
Drug: Sliding screw
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sliding screw device combined with calcium‐phosphate cement for augmentation
Study: 11227321
Drug: Psychodynamic oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic oriented psychotherapy in addition to standardized medical treatment
Study: 11227321
Drug: Standardized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized medical treatment (Control group)
Study: 7920211
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg/day) and vitamin A (25,000 international units/day)
Study: 31150601
Drug: US-guided standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided standard subacromial injection
Study: 31150601
Drug: Dual-target injection
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-target injection (subacromial bursa plus proximal biceps long-head tendon)
Study: 24919604
Drug: Wheat fibre
Normalized name: triticum (wheat fibre)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat fibre (15 g day⁻¹)
Study: 24919604
Drug: Inulin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (15 g day⁻¹)
Study: 24919604
Drug: Control (refined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (refined grain, 15 g day⁻¹)
Study: 15362934
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily of 95% ethyl esters of eicosapentaenoic acid (EPA)
Study: 10631623
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Paroxetine (comparison)
Study: 10631623
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and Venlafaxine (comparison)
Study: 10631623
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Venlafaxine
Study: 8725855
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.2 pmol . kg-1 . min-1)
Study: 3881104
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg/day and Propranolol 240 mg/day combined
Study: 29985236
Drug: Critical Administration
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical Administration Threshold (CAT+), defined as 3 U or greater RBC in the first hour
Study: 24915543
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil (2.4 g/day)
Study: 24915543
Drug: High-dose fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fish oil (16.2 g/day)
Study: 24382614
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 100% lavender oil (3 mL in a glass jar at bedside from 10 pm to 6 am)
Study: 24382614
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 100% lavender oil
Study: 22239862
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg once daily
Study: 22239862
Drug: Flibanserin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 50 mg twice daily
Study: 22239862
Drug: Flibanserin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 25 mg twice daily
Study: 19207432
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using indocyanine green (ICG) dye with a diode laser
Study: 17502777
Drug: Intramuscular biperiden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular biperiden
Study: 14982808
Drug: Albendazole formulations
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole formulations with arachis oil‐polysorbate 80
Study: 14982808
Drug: Albendazole formulations
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole formulations with hydroxypropyl‐beta‐cyclodextrin
Study: 14982808
Drug: Macrogol suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrogol suppositories
Study: 8633581
Drug: Sulfasalazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (3 g/day)
Study: 2568327
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nizatidine nightly
Study: 2568327
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 150 mg nizatidine daily
Study: 2568327
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 150 mg ranitidine daily
Study: 28096535
Drug: Germline SNPs
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germline SNPs associated with rapid drug clearance or drug resistance
Study: 28096535
Drug: Asparaginase resistance
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asparaginase resistance or allergy SNPs in treatment arms
Study: 24671237
Drug: GOS-containing infant
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS-containing infant formula (0.44 g/dl of GOS)